Lexicon Pharmaceuticals, Inc. (LXRX)

NASDAQ: LXRX · Real-Time Price · USD

2.320

-0.020 (-0.85%)

At close: Aug 14, 2026, 4:00 PM EDT

2.348

+0.028 (1.22%)

After-hours: Aug 14, 2026, 7:34 PM EDT

Lexicon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	41.47	49.8	31.08	1.2	0.14	0.3
Revenue Growth	-29.03%	60.24%	2481.48%	766.19%	-53.36%	-98.76%
Cost of Revenue	5.8	6.56	6.46	5.22	52.52	55.05
Gross Profit	35.67	43.24	24.63	-4.02	-52.38	-54.75
Selling, General & Admin	35.35	37.32	143.1	113.98	48.08	32.34
Research & Development	54.83	54.83	77.54	53.75	-	-
Operating Expenses	90.18	92.15	220.64	167.73	48.08	32.34
Operating Income	-54.5	-48.91	-196.02	-171.75	-100.46	-87.09
Interest Expense	-8.39	-8.34	-15.58	-13.1	-2.78	-0.8
Interest & Investment Income	6.12	6.91	12.29	7.73	1.6	0.13
EBT Excluding Unusual Items	-56.77	-50.34	-199.3	-177.12	-101.64	-87.76
Other Unusual Items	-4.35	-	-1.1	-	-0.3	-
Pretax Income	-61.12	-50.34	-200.4	-177.12	-101.94	-87.76
Net Income	-61.12	-50.34	-200.4	-177.12	-101.94	-87.76
Net Income to Common	-61.12	-50.34	-200.4	-177.12	-101.94	-87.76
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	391	363	320	221	166	146
Shares Outstanding (Diluted)	391	363	320	221	166	146
Shares Change	7.98%	13.44%	44.73%	33.42%	13.79%	31.41%
EPS (Basic)	-0.16	-0.14	-0.63	-0.80	-0.62	-0.60
EPS (Diluted)	-0.16	-0.14	-0.63	-0.80	-0.62	-0.60
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-64.99	-67.85	-179.81	-162.37	-90.18	-88.24
Free Cash Flow Per Share	-0.17	-0.19	-0.56	-0.73	-0.54	-0.61
Gross Margin	86.02%	86.82%	79.23%	-	-	-
Operating Margin	-131.43%	-98.21%	-630.67%	-14264.95%	-72273.38%	-29224.83%
Profit Margin	-147.38%	-101.08%	-644.78%	-14710.88%	-73341.01%	-29448.99%
Free Cash Flow Margin	-156.72%	-136.24%	-578.52%	-13485.63%	-64875.54%	-29610.07%
EBITDA	-54.02	-48.29	-195.48	-171.2	-100.03	-86.8
EBITDA Margin	-130.27%	-96.96%	-	-	-	-
D&A For EBITDA	0.48	0.62	0.53	0.55	0.43	0.29
EBIT	-54.5	-48.91	-196.02	-171.75	-100.46	-87.09
EBIT Margin	-131.43%	-98.21%	-	-	-	-
Revenue as Reported	41.47	49.8	31.08	1.2	0.14	0.3

SEC Filings: 10-K · 10-Q